The intratumoral administration of this engineered HSV prompts cancer cells to produce extended levels of GM-CSF locally, which attracts antigen-presenting cells through chemotaxis, initiating a local adaptive immune response to tumor antigens capable of cancer distant from the infusion site. Here, CSF2 is linked to neoplasm.